...
首页> 外文期刊>Oncology letters >RANKL: A promising circulating marker for bone metastasis response
【24h】

RANKL: A promising circulating marker for bone metastasis response

机译:RANKL:骨转移反应的有希望的循环标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Bone metastases are a frequent event in patients with solid tumors. Although great advances have been made in the treatment of these patients, the identification of novel, accurate indicators of bone response would greatly facilitate the clinical management of the disease. The receptor activator of nuclear factor-B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) signaling pathway is significantly involved in bone metastasis formation. The main aim of the present study was to evaluate the role of circulating RANK, RANKL and OPG levels in predicting bone response. Marker accuracy was also compared with that of the conventional tumor marker N-terminal telopeptide of type I collagen (NTX). A prospective study was performed on 49 patients with bone metastases from breast, lung and prostate cancer, who were undergoing treatment with zoledronic acid. Patients were monitored for 1 year with blood tests, clinical evaluation and instrumental exams according to the response evaluation criteria of the University of Texas M. D. Anderson Cancer Center (Houston, TX, USA) and the Positron Emission Tomography Response Criteria in Solid Tumors. Circulating RANK/RANKL/OPG transcripts and NTX levels were evaluated by reverse transcription-quantitative polymerase chain reaction and immune enzymatic assay, respectively. The baseline RANKL levels differed significantly between responders and non-responders, whereas no differences in NTX levels were observed between the two groups. Receiver operating characteristic curve evaluation for all markers revealed that RANKL was the most accurate marker, with an area under the curve of 0.74 (95% confidence interval, 0.54-0.93). In addition, RANKL, which is the target of the novel monoclonal antibody denosumab, was the most accurate predictor of bone response in the present series of patients with bone metastases. Thus, the use of RANKL as a marker could potentially improve clinical practice, as current bone response evaluation is still somewhat problematic.
机译:实体瘤患者经常发生骨转移。尽管在治疗这些患者方面已经取得了很大的进步,但是鉴定新颖,准确的骨反应指标将极大地促进该疾病的临床管理。核因子-B(RANK)/ RANK配体(RANKL)/骨保护素(OPG)信号通路的受体激活剂显着参与骨转移的形成。本研究的主要目的是评估循环RANK,RANKL和OPG水平在预测骨反应中的作用。还将标记准确性与I型胶原蛋白(NTX)的常规肿瘤标记N端端肽的准确性进行了比较。对接受唑来膦酸治疗的49例乳腺癌,肺癌和前列腺癌骨转移患者进行了前瞻性研究。根据德克萨斯大学安德森分校癌症中心(美国德克萨斯州休斯顿)的反应评估标准和正电子发射体层摄影术对实体瘤的反应标准,对患者进行了为期一年的血液检查,临床评估和仪器检查。循环RANK / RANKL / OPG转录本和NTX水平分别通过逆转录-定量聚合酶链反应和免疫酶法评估。应答者和非应答者之间的基线RANKL水平存在显着差异,而两组之间未观察到NTX水平的差异。对所有标记的接收器工作特性曲线评估表明,RANKL是最准确的标记,曲线下面积为0.74(95%置信区间,0.54-0.93)。此外,RANKL是新型单克隆抗体denosumab的靶标,它是本系列骨转移患者中最准确的骨反应预测指标。因此,将RANKL用作标记物可能会改善临床实践,因为当前的骨反应评估仍存在一些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号